Coeptis Therapeutics Inc. (COEP) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Coeptis Therapeutics Inc.

    NASDAQ: COEP · Real-Time Price · USD
    12.27
    0.38 (3.24%)
    At close: Sep 05, 2025, 3:59 PM
    12.27
    0.00%
    After-hours: Sep 05, 2025, 04:10 PM EDT

    Coeptis Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a n/a n/a 75K
    Cost of Revenue
    		 1.04M 1M 1M n/a
    Gross Profit
    		 -1.04M -1M -1M -372K
    Operating Income
    		 -10.05M -21.49M -34.2M -14.05M
    Interest Income
    		 n/a n/a n/a n/a
    Pretax Income
    		 -10.88M -21.27M -37.57M -13.45M
    Net Income
    		 -9.81M -21.27M -37.57M -13.45M
    Selling & General & Admin
    		 945.64K 13.82M 33.17M 14.12M
    Research & Development
    		 2.33M 6.67M 20.89K n/a
    Other Expenses
    		 6.78M n/a n/a n/a
    Operating Expenses
    		 10.05M 20.49M 33.2M 14.12M
    Interest Expense
    		 396.12K -108K 218.41K 187.13K
    Selling & Marketing Expenses
    		 n/a 12.71K 8.33K 2.92K
    Cost & Expenses
    		 10.05M 21.49M 34.2M 14.12M
    Income Tax Expense
    		 -1.06M n/a n/a n/a
    Shares Outstanding (Basic)
    		 1.93M 25.69M 14.3M 1.02M
    Shares Outstanding (Diluted)
    		 1.93M 25.69M 14.3M 1.02M
    EPS (Basic)
    		 -5.65 -0.83 -2.87 -13.16
    EPS (Diluted)
    		 -5.65 -0.83 -2.87 -13.16
    EBITDA
    		 -9.44M -20.16M -36.35M -12.81M
    EBIT
    		 -10.48M -21.16M -37.36M -13.26M
    Depreciation & Amortization
    		 1.04M 1M 1M 447.41K

    Add to Watchlist